<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <title>Ceftriaxone - Medications - Offline Clinical Reference</title>
  <link rel="stylesheet" href="../style.css">
</head>
<body>
  <div class="topbar">
    <div class="topbar-inner">
      <span class="pill"><strong>Ceftriaxone</strong></span>
      <span class="spacer"></span>
      <div class="nav-btns">
        <a class="btn small" href="../index.html">Home</a>
        <a class="btn small" href="../medications.html">Back to Medications</a>
      </div>
    </div>
  </div>

  <main class="wrap">
    <section class="section">
      <div class="kicker">Antibiotics / Antivirals</div>
      <h1>Ceftriaxone</h1>

      <div class="content">
        <h3>Stocked on board</h3>
        <ul>
          <li>Ceftriaxone 250mg Injection</li>
        </ul>

        <div class="rule"></div>

        <h3>Adult dosing</h3>
        <ul>
          <li><strong>Gonorrhea (uncomplicated urethral, cervical, rectal, pharyngeal)</strong>
            <ul>
              <li>250 mg IM single dose (single-dose vial stocked onboard)</li>
              <li>Note: Current Canadian guidelines may recommend dual therapy with azithromycin; verify local protocol</li>
            </ul>
          </li>
          <li><strong>Community-acquired pneumonia (moderate to severe; inpatient)</strong>
            <ul>
              <li>1–2 g IV/IM once daily</li>
            </ul>
          </li>
          <li><strong>Meningitis (bacterial; empiric or specific pathogen)</strong>
            <ul>
              <li>2 g IV every 12 hours (typically in combination therapy; provider-directed)</li>
            </ul>
          </li>
          <li><strong>Intra-abdominal infections (moderate to severe)</strong>
            <ul>
              <li>1–2 g IV/IM once daily (often combined with metronidazole for anaerobic coverage)</li>
            </ul>
          </li>
          <li><strong>Pelvic inflammatory disease (inpatient treatment)</strong>
            <ul>
              <li>250 mg IM single dose, then continue with oral doxycycline (or per protocol)</li>
            </ul>
          </li>
          <li><strong>Skin and soft tissue infections (severe)</strong>
            <ul>
              <li>1–2 g IV/IM once daily</li>
            </ul>
          </li>
          <li><strong>Urinary tract infections (complicated; pyelonephritis)</strong>
            <ul>
              <li>1–2 g IV/IM once daily</li>
            </ul>
          </li>
          <li><strong>Renal impairment dosing</strong>
            <ul>
              <li>No dose adjustment required unless concurrent severe hepatic impairment (dual elimination: renal + biliary)</li>
            </ul>
          </li>
        </ul>

        <div class="rule"></div>

        <h3>Indications</h3>
        <ul>
          <li>Uncomplicated gonorrhea (single-dose IM therapy)</li>
          <li>Severe bacterial infections requiring parenteral therapy (pneumonia, meningitis, sepsis)</li>
          <li>Intra-abdominal infections (often combined with anaerobic coverage)</li>
          <li>Pelvic inflammatory disease</li>
          <li>Skin and soft tissue infections (severe)</li>
          <li>Complicated urinary tract infections / pyelonephritis</li>
          <li>Third-generation cephalosporin with excellent gram-negative and some gram-positive coverage; long half-life allows once-daily dosing</li>
        </ul>

        <div class="rule"></div>

        <h3>Contraindications / cautions</h3>
        <ul>
          <li>Hypersensitivity to ceftriaxone or other cephalosporins</li>
          <li>History of immediate/severe hypersensitivity to penicillins (risk of cross-reactivity; assess severity and type of reaction)</li>
          <li>Hyperbilirubinemic neonates (can displace bilirubin; contraindicated in neonates)</li>
          <li>Concurrent IV calcium-containing solutions (precipitation risk; do not mix)</li>
          <li>C. difficile-associated diarrhea risk: reassess if significant diarrhea develops during/after therapy</li>
          <li>Not effective against MRSA, Enterococcus, Pseudomonas, or anaerobes (add metronidazole for anaerobic coverage if needed)</li>
          <li>Biliary sludging/pseudolithiasis (rare; more common with prolonged high-dose therapy)</li>
        </ul>

        <div class="rule"></div>

        <h3>Adverse effects</h3>
        <ul>
          <li>Injection site reactions (pain, induration at IM site; phlebitis with IV)</li>
          <li>Hypersensitivity reactions (rash, urticaria; rarely anaphylaxis)</li>
          <li>GI upset (nausea, diarrhea)</li>
          <li>C. difficile-associated diarrhea</li>
          <li>Elevated liver enzymes (transient)</li>
          <li>Hematologic effects (eosinophilia, thrombocytopenia, leukopenia – uncommon)</li>
          <li>Biliary sludging/pseudolithiasis (usually reversible; more common with high doses or prolonged therapy)</li>
        </ul>

        <div class="rule"></div>

        <h3>Preparation &amp; administration</h3>
        <ul>
          <li><strong>IM administration (gonorrhea; 250 mg dose):</strong>
            <ul>
              <li>Reconstitute powder with 1% lidocaine (without epinephrine) per manufacturer's instructions to reduce injection pain</li>
              <li>Administer deep IM into large muscle mass (gluteal or lateral thigh)</li>
              <li>Typical reconstitution: 250 mg vial with 0.9 mL diluent</li>
            </ul>
          </li>
          <li><strong>IV administration (higher doses):</strong>
            <ul>
              <li>Reconstitute with sterile water for injection or 0.9% sodium chloride</li>
              <li>May give as slow IV push over 2–4 minutes (concentrated) or dilute further and infuse over 30 minutes</li>
            </ul>
          </li>
          <li>Once-daily dosing: administer at the same time each day</li>
          <li>Do not mix with calcium-containing solutions (precipitation risk)</li>
          <li>Discard unused reconstituted solution per stability guidelines (varies by diluent; typically 24 hours refrigerated)</li>
          <li>Inspect for particulate matter and discoloration before administration</li>
        </ul>

        <div class="rule"></div>

        <h3>Monitoring</h3>
        <ul>
          <li>Clinical response within 48–72 hours (fever, infection signs, symptoms)</li>
          <li>Allergy/hypersensitivity reactions (rash, anaphylaxis): stop immediately if anaphylaxis suspected</li>
          <li>Diarrhea severity (assess for C. difficile if severe/persistent)</li>
          <li>For gonorrhea treatment: test of cure recommended (especially pharyngeal infections); follow local STI guidelines and ensure partner notification</li>
          <li>Liver function tests and CBC if prolonged therapy (monitor for elevated enzymes, hematologic effects)</li>
          <li>Signs of biliary sludging if prolonged high-dose therapy (right upper quadrant pain, nausea)</li>
        </ul>

        <div class="rule"></div>

        <h3>At-sea considerations</h3>
        <ul>
          <li>Excellent single-dose IM therapy for uncomplicated gonorrhea (250 mg dose stocked onboard)</li>
          <li>Long half-life allows once-daily dosing for severe infections requiring parenteral therapy</li>
          <li>For gonorrhea: verify current dosing recommendations and dual therapy guidelines; ensure partner management per public health protocol</li>
          <li>Broad-spectrum coverage but lacks anaerobic activity: add metronidazole for intra-abdominal/gynecologic infections when needed</li>
          <li>Confirm indication and avoid antibiotics for likely viral/self-limited illness when possible (stewardship)</li>
          <li>IM injection can be painful: use lidocaine reconstitution and warn patient</li>
          <li>Document start date, dose, planned duration, and allergy status clearly</li>
        </ul>

        <div class="rule"></div>

        <h3>Online-only references</h3>
        <ul>
          <li>Health Canada product monograph (Ceftriaxone for Injection): <a href="https://pdf.hres.ca/dpd_pm/00067817.PDF" target="_blank" rel="noopener">https://pdf.hres.ca/dpd_pm/00067817.PDF</a></li>
          <li>Canadian Guidelines on Sexually Transmitted Infections – Gonococcal Infections: <a href="https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/gonococcal-infections.html" target="_blank" rel="noopener">https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/gonococcal-infections.html</a></li>
          <li>Sanford Guide to Antimicrobial Therapy (subscription): <a href="https://www.sanfordguide.com/" target="_blank" rel="noopener">https://www.sanfordguide.com/</a></li>
        </ul>
      </div>

      <p class="foot">
        Verify dosing and indications against current clinical guidelines.
      </p>
    </section>
  </main>
</body>
</html>
